Compare Sanofi SA (SNY) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Symbotic Inc — how do they compare? Sanofi SA trades at $43.48 (market cap $104.30B), while Symbotic Inc trades at $41.41 (market cap $5.41B). The key difference: Sanofi SA is far larger — about 19.3× Symbotic Inc's market cap, and Sanofi SA pays a 5.55% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| SNY | SYM | |
|---|---|---|
Market Cap | $104.30B | $5.41B |
Sector | Health | Technology |
52-Week High | $52.34 | $87.30 |
52-Week Low | $41.33 | $38.57 |
Enterprise Value | $124.19B | $3.67B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
SYM trades at $41.17, up 2.64% today but facing bearish technical signals with 15 sell indicators. The company reported mixed Q3 2026 results with revenue growth of 21.7% but an earnings miss. Despite negative net income of -$16.94M in 2025, cash flow remains strong at $516.84M and analysts maintain a $60 consensus target with 61% buy ratings.
SYM presents a growth story with expanding revenue and margin improvements, but faces execution risks amid recent earnings misses. The stock offers potential upside to analyst targets but requires careful monitoring of profitability trends and competitive pressures in the warehouse automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
